CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc. (CASI) Stock Competitors & Peer Comparison
See (CASI) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CASI | $0.80 | +285.54% | 3.2M | -0.07 | -$3.02 | N/A |
| VRTX | $480.13 | -0.60% | 122B | 31.36 | $15.31 | N/A |
| REGN | $770.79 | -1.72% | 80.1B | 18.59 | $41.47 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $771.53 | -5.56% | 47.7B | 33.00 | $23.38 | N/A |
| ALNY | $331.24 | +1.25% | 43.9B | 142.16 | $2.33 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| INSM | $150.00 | +0.94% | 32B | -24.23 | -$6.19 | N/A |
| BNTX | $108.80 | -0.95% | 26.2B | -39.00 | -$2.79 | N/A |
| UTHR | $503.60 | -5.89% | 22.8B | 19.10 | $26.37 | N/A |
Stock Comparison
CASI vs VRTX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, VRTX has a market cap of 122B. Regarding current trading prices, CASI is priced at $0.80, while VRTX trades at $480.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas VRTX's P/E ratio is 31.36. In terms of profitability, CASI's ROE is +3.58%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, CASI is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check VRTX's competition here
CASI vs REGN Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, REGN has a market cap of 80.1B. Regarding current trading prices, CASI is priced at $0.80, while REGN trades at $770.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas REGN's P/E ratio is 18.59. In terms of profitability, CASI's ROE is +3.58%, compared to REGN's ROE of +0.15%. Regarding short-term risk, CASI is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check REGN's competition here
CASI vs VRNA Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CASI is priced at $0.80, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CASI's ROE is +3.58%, compared to VRNA's ROE of -0.30%. Regarding short-term risk, CASI is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check VRNA's competition here
CASI vs ARGX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ARGX has a market cap of 47.7B. Regarding current trading prices, CASI is priced at $0.80, while ARGX trades at $771.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ARGX's P/E ratio is 33.00. In terms of profitability, CASI's ROE is +3.58%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, CASI is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check ARGX's competition here
CASI vs ALNY Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ALNY has a market cap of 43.9B. Regarding current trading prices, CASI is priced at $0.80, while ALNY trades at $331.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ALNY's P/E ratio is 142.16. In terms of profitability, CASI's ROE is +3.58%, compared to ALNY's ROE of +0.90%. Regarding short-term risk, CASI is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check ALNY's competition here
CASI vs SGEN Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CASI is priced at $0.80, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CASI's ROE is +3.58%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CASI is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check SGEN's competition here
CASI vs INSM Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, INSM has a market cap of 32B. Regarding current trading prices, CASI is priced at $0.80, while INSM trades at $150.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas INSM's P/E ratio is -24.23. In terms of profitability, CASI's ROE is +3.58%, compared to INSM's ROE of -1.68%. Regarding short-term risk, CASI is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check INSM's competition here
CASI vs BNTX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, BNTX has a market cap of 26.2B. Regarding current trading prices, CASI is priced at $0.80, while BNTX trades at $108.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas BNTX's P/E ratio is -39.00. In terms of profitability, CASI's ROE is +3.58%, compared to BNTX's ROE of -0.03%. Regarding short-term risk, CASI is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check BNTX's competition here
CASI vs UTHR Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, UTHR has a market cap of 22.8B. Regarding current trading prices, CASI is priced at $0.80, while UTHR trades at $503.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas UTHR's P/E ratio is 19.10. In terms of profitability, CASI's ROE is +3.58%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CASI is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check UTHR's competition here
CASI vs ROIV Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ROIV has a market cap of 20.4B. Regarding current trading prices, CASI is priced at $0.80, while ROIV trades at $28.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ROIV's P/E ratio is -24.35. In terms of profitability, CASI's ROE is +3.58%, compared to ROIV's ROE of -0.18%. Regarding short-term risk, CASI is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check ROIV's competition here
CASI vs BGNE Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CASI is priced at $0.80, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CASI's ROE is +3.58%, compared to BGNE's ROE of +0.02%. Regarding short-term risk, CASI is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check BGNE's competition here
CASI vs MRNA Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, MRNA has a market cap of 20.2B. Regarding current trading prices, CASI is priced at $0.80, while MRNA trades at $51.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas MRNA's P/E ratio is -7.01. In terms of profitability, CASI's ROE is +3.58%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, CASI is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check MRNA's competition here
CASI vs INCY Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, INCY has a market cap of 19.9B. Regarding current trading prices, CASI is priced at $0.80, while INCY trades at $100.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas INCY's P/E ratio is 15.61. In terms of profitability, CASI's ROE is +3.58%, compared to INCY's ROE of +0.29%. Regarding short-term risk, CASI is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check INCY's competition here
CASI vs RVMD Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, RVMD has a market cap of 19.7B. Regarding current trading prices, CASI is priced at $0.80, while RVMD trades at $102.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas RVMD's P/E ratio is -19.68. In terms of profitability, CASI's ROE is +3.58%, compared to RVMD's ROE of -0.54%. Regarding short-term risk, CASI is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check RVMD's competition here
CASI vs RPRX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, RPRX has a market cap of 19.4B. Regarding current trading prices, CASI is priced at $0.80, while RPRX trades at $45.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas RPRX's P/E ratio is 25.48. In terms of profitability, CASI's ROE is +3.58%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, CASI is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check RPRX's competition here
CASI vs DNA-WT Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CASI is priced at $0.80, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CASI's ROE is +3.58%, compared to DNA-WT's ROE of -0.54%. Regarding short-term risk, CASI is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check DNA-WT's competition here
CASI vs GMAB Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, GMAB has a market cap of 18B. Regarding current trading prices, CASI is priced at $0.80, while GMAB trades at $29.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas GMAB's P/E ratio is 18.99. In terms of profitability, CASI's ROE is +3.58%, compared to GMAB's ROE of +0.11%. Regarding short-term risk, CASI is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check GMAB's competition here
CASI vs ASND Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ASND has a market cap of 14.1B. Regarding current trading prices, CASI is priced at $0.80, while ASND trades at $228.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ASND's P/E ratio is -51.57. In terms of profitability, CASI's ROE is +3.58%, compared to ASND's ROE of +1.28%. Regarding short-term risk, CASI is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check ASND's competition here
CASI vs IONS Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, IONS has a market cap of 13.1B. Regarding current trading prices, CASI is priced at $0.80, while IONS trades at $80.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas IONS's P/E ratio is -50.06. In terms of profitability, CASI's ROE is +3.58%, compared to IONS's ROE of -0.69%. Regarding short-term risk, CASI is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check IONS's competition here
CASI vs BBIO Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, CASI is priced at $0.80, while BBIO trades at $67.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas BBIO's P/E ratio is -16.06. In terms of profitability, CASI's ROE is +3.58%, compared to BBIO's ROE of +0.39%. Regarding short-term risk, CASI is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check BBIO's competition here
CASI vs KRTX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CASI is priced at $0.80, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CASI's ROE is +3.58%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CASI is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check KRTX's competition here
CASI vs EXEL Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, EXEL has a market cap of 11.9B. Regarding current trading prices, CASI is priced at $0.80, while EXEL trades at $44.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas EXEL's P/E ratio is 15.93. In terms of profitability, CASI's ROE is +3.58%, compared to EXEL's ROE of +0.37%. Regarding short-term risk, CASI is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check EXEL's competition here
CASI vs SMMT Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, SMMT has a market cap of 11.8B. Regarding current trading prices, CASI is priced at $0.80, while SMMT trades at $15.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas SMMT's P/E ratio is -12.64. In terms of profitability, CASI's ROE is +3.58%, compared to SMMT's ROE of -2.97%. Regarding short-term risk, CASI is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check SMMT's competition here
CASI vs BMRN Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, BMRN has a market cap of 11.7B. Regarding current trading prices, CASI is priced at $0.80, while BMRN trades at $61.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas BMRN's P/E ratio is 22.72. In terms of profitability, CASI's ROE is +3.58%, compared to BMRN's ROE of +0.06%. Regarding short-term risk, CASI is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check BMRN's competition here
CASI vs JAZZ Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, JAZZ has a market cap of 11.5B. Regarding current trading prices, CASI is priced at $0.80, while JAZZ trades at $188.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas JAZZ's P/E ratio is -30.68. In terms of profitability, CASI's ROE is +3.58%, compared to JAZZ's ROE of -0.09%. Regarding short-term risk, CASI is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check JAZZ's competition here
CASI vs RNA Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, RNA has a market cap of 11.2B. Regarding current trading prices, CASI is priced at $0.80, while RNA trades at $72.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas RNA's P/E ratio is -17.37. In terms of profitability, CASI's ROE is +3.58%, compared to RNA's ROE of -0.45%. Regarding short-term risk, CASI is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check RNA's competition here
CASI vs MDGL Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, MDGL has a market cap of 10.1B. Regarding current trading prices, CASI is priced at $0.80, while MDGL trades at $445.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas MDGL's P/E ratio is -34.67. In terms of profitability, CASI's ROE is +3.58%, compared to MDGL's ROE of -0.44%. Regarding short-term risk, CASI is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check MDGL's competition here
CASI vs RXDX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CASI is priced at $0.80, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CASI's ROE is +3.58%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CASI is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check RXDX's competition here
CASI vs IBRX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, IBRX has a market cap of 9.4B. Regarding current trading prices, CASI is priced at $0.80, while IBRX trades at $9.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas IBRX's P/E ratio is -23.29. In terms of profitability, CASI's ROE is +3.58%, compared to IBRX's ROE of +0.64%. Regarding short-term risk, CASI is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check IBRX's competition here
CASI vs TECH Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, TECH has a market cap of 9.1B. Regarding current trading prices, CASI is priced at $0.80, while TECH trades at $57.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas TECH's P/E ratio is 109.28. In terms of profitability, CASI's ROE is +3.58%, compared to TECH's ROE of +0.04%. Regarding short-term risk, CASI is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check TECH's competition here
CASI vs ARWR Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ARWR has a market cap of 8.9B. Regarding current trading prices, CASI is priced at $0.80, while ARWR trades at $63.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ARWR's P/E ratio is 39.59. In terms of profitability, CASI's ROE is +3.58%, compared to ARWR's ROE of +0.36%. Regarding short-term risk, CASI is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check ARWR's competition here
CASI vs IMGN Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CASI is priced at $0.80, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CASI's ROE is +3.58%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CASI is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check IMGN's competition here
CASI vs PCVX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, PCVX has a market cap of 8.6B. Regarding current trading prices, CASI is priced at $0.80, while PCVX trades at $60.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas PCVX's P/E ratio is -12.37. In terms of profitability, CASI's ROE is +3.58%, compared to PCVX's ROE of -0.26%. Regarding short-term risk, CASI is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check PCVX's competition here
CASI vs BPMC Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CASI is priced at $0.80, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CASI's ROE is +3.58%, compared to BPMC's ROE of -0.33%. Regarding short-term risk, CASI is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check BPMC's competition here
CASI vs AXSM Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, AXSM has a market cap of 8.2B. Regarding current trading prices, CASI is priced at $0.80, while AXSM trades at $163.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas AXSM's P/E ratio is -34.94. In terms of profitability, CASI's ROE is +3.58%, compared to AXSM's ROE of -2.54%. Regarding short-term risk, CASI is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check AXSM's competition here
CASI vs CERE Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CASI is priced at $0.80, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas CERE's P/E ratio is -16.47. In terms of profitability, CASI's ROE is +3.58%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CASI is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check CERE's competition here
CASI vs HALO Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, HALO has a market cap of 8.2B. Regarding current trading prices, CASI is priced at $0.80, while HALO trades at $69.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas HALO's P/E ratio is 27.04. In terms of profitability, CASI's ROE is +3.58%, compared to HALO's ROE of +0.93%. Regarding short-term risk, CASI is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check HALO's competition here
CASI vs KRYS Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, KRYS has a market cap of 8.1B. Regarding current trading prices, CASI is priced at $0.80, while KRYS trades at $276.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas KRYS's P/E ratio is 41.37. In terms of profitability, CASI's ROE is +3.58%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CASI is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check KRYS's competition here
CASI vs ABVX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ABVX has a market cap of 7.8B. Regarding current trading prices, CASI is priced at $0.80, while ABVX trades at $119.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ABVX's P/E ratio is -22.83. In terms of profitability, CASI's ROE is +3.58%, compared to ABVX's ROE of +50.78%. Regarding short-term risk, CASI is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check ABVX's competition here
CASI vs CYTK Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, CYTK has a market cap of 7.7B. Regarding current trading prices, CASI is priced at $0.80, while CYTK trades at $62.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas CYTK's P/E ratio is -9.94. In terms of profitability, CASI's ROE is +3.58%, compared to CYTK's ROE of +2.33%. Regarding short-term risk, CASI is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check CYTK's competition here
CASI vs KYMR Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, KYMR has a market cap of 7.6B. Regarding current trading prices, CASI is priced at $0.80, while KYMR trades at $95.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas KYMR's P/E ratio is -26.40. In terms of profitability, CASI's ROE is +3.58%, compared to KYMR's ROE of -0.29%. Regarding short-term risk, CASI is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for CASI.Check KYMR's competition here
CASI vs NUVL Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, NUVL has a market cap of 7.6B. Regarding current trading prices, CASI is priced at $0.80, while NUVL trades at $103.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas NUVL's P/E ratio is -19.50. In terms of profitability, CASI's ROE is +3.58%, compared to NUVL's ROE of -0.39%. Regarding short-term risk, CASI is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check NUVL's competition here
CASI vs MTSR Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CASI is priced at $0.80, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CASI's ROE is +3.58%, compared to MTSR's ROE of -0.80%. Regarding short-term risk, CASI is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check MTSR's competition here
CASI vs PRAX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, PRAX has a market cap of 7.2B. Regarding current trading prices, CASI is priced at $0.80, while PRAX trades at $340.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas PRAX's P/E ratio is -26.21. In terms of profitability, CASI's ROE is +3.58%, compared to PRAX's ROE of -0.59%. Regarding short-term risk, CASI is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check PRAX's competition here
CASI vs MRUS Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CASI is priced at $0.80, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CASI's ROE is +3.58%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, CASI is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check MRUS's competition here
CASI vs ACLX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ACLX has a market cap of 6.6B. Regarding current trading prices, CASI is priced at $0.80, while ACLX trades at $113.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ACLX's P/E ratio is -29.05. In terms of profitability, CASI's ROE is +3.58%, compared to ACLX's ROE of -0.51%. Regarding short-term risk, CASI is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check ACLX's competition here
CASI vs BLTE Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, CASI is priced at $0.80, while BLTE trades at $188.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas BLTE's P/E ratio is -98.20. In terms of profitability, CASI's ROE is +3.58%, compared to BLTE's ROE of -0.34%. Regarding short-term risk, CASI is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check BLTE's competition here
CASI vs RETA Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CASI is priced at $0.80, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas RETA's P/E ratio is -66.29. In terms of profitability, CASI's ROE is +3.58%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CASI is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check RETA's competition here
CASI vs RYTM Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, RYTM has a market cap of 6.5B. Regarding current trading prices, CASI is priced at $0.80, while RYTM trades at $98.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas RYTM's P/E ratio is -31.64. In terms of profitability, CASI's ROE is +3.58%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, CASI is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check RYTM's competition here
CASI vs COGT Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, COGT has a market cap of 6.4B. Regarding current trading prices, CASI is priced at $0.80, while COGT trades at $39.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas COGT's P/E ratio is -19.25. In terms of profitability, CASI's ROE is +3.58%, compared to COGT's ROE of -1.00%. Regarding short-term risk, CASI is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check COGT's competition here
CASI vs CRSP Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, CRSP has a market cap of 5.9B. Regarding current trading prices, CASI is priced at $0.80, while CRSP trades at $61.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas CRSP's P/E ratio is -9.54. In terms of profitability, CASI's ROE is +3.58%, compared to CRSP's ROE of -0.32%. Regarding short-term risk, CASI is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for CASI.Check CRSP's competition here
CASI vs CDTX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CASI is priced at $0.80, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CASI's ROE is +3.58%, compared to CDTX's ROE of -0.60%. Regarding short-term risk, CASI is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check CDTX's competition here
CASI vs IMVT Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, IMVT has a market cap of 5.6B. Regarding current trading prices, CASI is priced at $0.80, while IMVT trades at $27.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas IMVT's P/E ratio is -10.27. In terms of profitability, CASI's ROE is +3.58%, compared to IMVT's ROE of -0.66%. Regarding short-term risk, CASI is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check IMVT's competition here
CASI vs PTGX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, PTGX has a market cap of 5.5B. Regarding current trading prices, CASI is priced at $0.80, while PTGX trades at $88.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas PTGX's P/E ratio is 133.92. In terms of profitability, CASI's ROE is +3.58%, compared to PTGX's ROE of +0.07%. Regarding short-term risk, CASI is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check PTGX's competition here
CASI vs ABCM Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CASI is priced at $0.80, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CASI's ROE is +3.58%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CASI is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check ABCM's competition here
CASI vs ISEE Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CASI is priced at $0.80, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CASI's ROE is +3.58%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CASI is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check ISEE's competition here
CASI vs PTCT Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, CASI is priced at $0.80, while PTCT trades at $68.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas PTCT's P/E ratio is 7.92. In terms of profitability, CASI's ROE is +3.58%, compared to PTCT's ROE of -3.62%. Regarding short-term risk, CASI is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check PTCT's competition here
CASI vs CAI Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, CAI has a market cap of 5.4B. Regarding current trading prices, CASI is priced at $0.80, while CAI trades at $19.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas CAI's P/E ratio is -5.47. In terms of profitability, CASI's ROE is +3.58%, compared to CAI's ROE of +0.27%. Regarding short-term risk, CASI is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check CAI's competition here
CASI vs FBIOX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, FBIOX has a market cap of 5.2B. Regarding current trading prices, CASI is priced at $0.80, while FBIOX trades at $25.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas FBIOX's P/E ratio is N/A. In terms of profitability, CASI's ROE is +3.58%, compared to FBIOX's ROE of +0.00%. Regarding short-term risk, CASI is more volatile compared to FBIOX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check FBIOX's competition here
CASI vs CELC Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, CELC has a market cap of 5.1B. Regarding current trading prices, CASI is priced at $0.80, while CELC trades at $111.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas CELC's P/E ratio is -30.03. In terms of profitability, CASI's ROE is +3.58%, compared to CELC's ROE of -1.79%. Regarding short-term risk, CASI is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check CELC's competition here
CASI vs ALKS Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ALKS has a market cap of 5.1B. Regarding current trading prices, CASI is priced at $0.80, while ALKS trades at $30.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ALKS's P/E ratio is 15.29. In terms of profitability, CASI's ROE is +3.58%, compared to ALKS's ROE of +0.14%. Regarding short-term risk, CASI is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check ALKS's competition here
CASI vs TGTX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, TGTX has a market cap of 4.9B. Regarding current trading prices, CASI is priced at $0.80, while TGTX trades at $30.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas TGTX's P/E ratio is 11.16. In terms of profitability, CASI's ROE is +3.58%, compared to TGTX's ROE of +1.33%. Regarding short-term risk, CASI is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check TGTX's competition here
CASI vs MIRM Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, MIRM has a market cap of 4.8B. Regarding current trading prices, CASI is priced at $0.80, while MIRM trades at $92.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas MIRM's P/E ratio is -109.75. In terms of profitability, CASI's ROE is +3.58%, compared to MIRM's ROE of -0.09%. Regarding short-term risk, CASI is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check MIRM's competition here
CASI vs SRRK Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, SRRK has a market cap of 4.6B. Regarding current trading prices, CASI is priced at $0.80, while SRRK trades at $44.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas SRRK's P/E ratio is -14.23. In terms of profitability, CASI's ROE is +3.58%, compared to SRRK's ROE of -1.22%. Regarding short-term risk, CASI is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check SRRK's competition here
CASI vs CGON Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, CGON has a market cap of 4.5B. Regarding current trading prices, CASI is priced at $0.80, while CGON trades at $56.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas CGON's P/E ratio is -27.37. In terms of profitability, CASI's ROE is +3.58%, compared to CGON's ROE of -0.22%. Regarding short-term risk, CASI is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check CGON's competition here
CASI vs AKRO Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CASI is priced at $0.80, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CASI's ROE is +3.58%, compared to AKRO's ROE of -0.31%. Regarding short-term risk, CASI is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check AKRO's competition here
CASI vs FOLD Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CASI is priced at $0.80, while FOLD trades at $14.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas FOLD's P/E ratio is -358.25. In terms of profitability, CASI's ROE is +3.58%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CASI is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check FOLD's competition here
CASI vs CRNX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, CRNX has a market cap of 4.5B. Regarding current trading prices, CASI is priced at $0.80, while CRNX trades at $43.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas CRNX's P/E ratio is -9.66. In terms of profitability, CASI's ROE is +3.58%, compared to CRNX's ROE of -0.35%. Regarding short-term risk, CASI is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check CRNX's competition here
CASI vs ALPN Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CASI is priced at $0.80, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CASI's ROE is +3.58%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CASI is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check ALPN's competition here
CASI vs OPT Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CASI is priced at $0.80, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas OPT's P/E ratio is -1.52. In terms of profitability, CASI's ROE is +3.58%, compared to OPT's ROE of +0.88%. Regarding short-term risk, CASI is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check OPT's competition here
CASI vs ERAS Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ERAS has a market cap of 4.2B. Regarding current trading prices, CASI is priced at $0.80, while ERAS trades at $13.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ERAS's P/E ratio is -31.56. In terms of profitability, CASI's ROE is +3.58%, compared to ERAS's ROE of -0.33%. Regarding short-term risk, CASI is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check ERAS's competition here
CASI vs ACAD Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ACAD has a market cap of 4.2B. Regarding current trading prices, CASI is priced at $0.80, while ACAD trades at $24.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ACAD's P/E ratio is 15.90. In terms of profitability, CASI's ROE is +3.58%, compared to ACAD's ROE of +0.42%. Regarding short-term risk, CASI is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check ACAD's competition here
CASI vs MRTX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CASI is priced at $0.80, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CASI's ROE is +3.58%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CASI is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check MRTX's competition here
CASI vs NAMS Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, NAMS has a market cap of 3.9B. Regarding current trading prices, CASI is priced at $0.80, while NAMS trades at $34.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas NAMS's P/E ratio is -19.93. In terms of profitability, CASI's ROE is +3.58%, compared to NAMS's ROE of -0.27%. Regarding short-term risk, CASI is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check NAMS's competition here
CASI vs LGND Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, LGND has a market cap of 3.9B. Regarding current trading prices, CASI is priced at $0.80, while LGND trades at $196.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas LGND's P/E ratio is 86.42. In terms of profitability, CASI's ROE is +3.58%, compared to LGND's ROE of +0.06%. Regarding short-term risk, CASI is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check LGND's competition here
CASI vs VKTX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, VKTX has a market cap of 3.8B. Regarding current trading prices, CASI is priced at $0.80, while VKTX trades at $32.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas VKTX's P/E ratio is -10.34. In terms of profitability, CASI's ROE is +3.58%, compared to VKTX's ROE of -0.48%. Regarding short-term risk, CASI is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check VKTX's competition here
CASI vs APGE Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, APGE has a market cap of 3.8B. Regarding current trading prices, CASI is priced at $0.80, while APGE trades at $69.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas APGE's P/E ratio is -15.77. In terms of profitability, CASI's ROE is +3.58%, compared to APGE's ROE of -0.39%. Regarding short-term risk, CASI is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check APGE's competition here
CASI vs CORT Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, CORT has a market cap of 3.8B. Regarding current trading prices, CASI is priced at $0.80, while CORT trades at $35.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas CORT's P/E ratio is 41.13. In terms of profitability, CASI's ROE is +3.58%, compared to CORT's ROE of +0.15%. Regarding short-term risk, CASI is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check CORT's competition here
CASI vs RYZB Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CASI is priced at $0.80, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CASI's ROE is +3.58%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CASI is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check RYZB's competition here
CASI vs CBAY Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CASI is priced at $0.80, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CASI's ROE is +3.58%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CASI is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check CBAY's competition here
CASI vs GPCR Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, GPCR has a market cap of 3.7B. Regarding current trading prices, CASI is priced at $0.80, while GPCR trades at $64.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas GPCR's P/E ratio is -17.69. In terms of profitability, CASI's ROE is +3.58%, compared to GPCR's ROE of -0.26%. Regarding short-term risk, CASI is more volatile compared to GPCR. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check GPCR's competition here
CASI vs TERN Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, TERN has a market cap of 3.7B. Regarding current trading prices, CASI is priced at $0.80, while TERN trades at $40.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas TERN's P/E ratio is -40.12. In terms of profitability, CASI's ROE is +3.58%, compared to TERN's ROE of -0.30%. Regarding short-term risk, CASI is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check TERN's competition here
CASI vs ADMA Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ADMA has a market cap of 3.6B. Regarding current trading prices, CASI is priced at $0.80, while ADMA trades at $15.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ADMA's P/E ratio is 17.65. In terms of profitability, CASI's ROE is +3.58%, compared to ADMA's ROE of +0.35%. Regarding short-term risk, CASI is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for CASI.Check ADMA's competition here
CASI vs CNTA Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, CNTA has a market cap of 3.6B. Regarding current trading prices, CASI is priced at $0.80, while CNTA trades at $26.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas CNTA's P/E ratio is -14.16. In terms of profitability, CASI's ROE is +3.58%, compared to CNTA's ROE of -0.68%. Regarding short-term risk, CASI is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check CNTA's competition here
CASI vs SWTX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CASI is priced at $0.80, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CASI's ROE is +3.58%, compared to SWTX's ROE of -0.45%. Regarding short-term risk, CASI is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check SWTX's competition here
CASI vs ARQT Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, CASI is priced at $0.80, while ARQT trades at $28.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ARQT's P/E ratio is -84.03. In terms of profitability, CASI's ROE is +3.58%, compared to ARQT's ROE of -0.10%. Regarding short-term risk, CASI is less volatile compared to ARQT. This indicates potentially lower risk in terms of short-term price fluctuations for CASI.Check ARQT's competition here
CASI vs XENE Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, XENE has a market cap of 3.5B. Regarding current trading prices, CASI is priced at $0.80, while XENE trades at $44.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas XENE's P/E ratio is -11.55. In terms of profitability, CASI's ROE is +3.58%, compared to XENE's ROE of -0.46%. Regarding short-term risk, CASI is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check XENE's competition here
CASI vs DNLI Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, DNLI has a market cap of 3.3B. Regarding current trading prices, CASI is priced at $0.80, while DNLI trades at $21.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas DNLI's P/E ratio is -7.34. In terms of profitability, CASI's ROE is +3.58%, compared to DNLI's ROE of -0.46%. Regarding short-term risk, CASI is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check DNLI's competition here
CASI vs KNSA Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, KNSA has a market cap of 3.2B. Regarding current trading prices, CASI is priced at $0.80, while KNSA trades at $43.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas KNSA's P/E ratio is 96.64. In terms of profitability, CASI's ROE is +3.58%, compared to KNSA's ROE of +0.23%. Regarding short-term risk, CASI is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check KNSA's competition here
CASI vs TARS Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, TARS has a market cap of 3.2B. Regarding current trading prices, CASI is priced at $0.80, while TARS trades at $75.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas TARS's P/E ratio is -38.13. In terms of profitability, CASI's ROE is +3.58%, compared to TARS's ROE of -0.20%. Regarding short-term risk, CASI is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check TARS's competition here
CASI vs EWTX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, EWTX has a market cap of 3.1B. Regarding current trading prices, CASI is priced at $0.80, while EWTX trades at $29.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas EWTX's P/E ratio is -18.89. In terms of profitability, CASI's ROE is +3.58%, compared to EWTX's ROE of -0.30%. Regarding short-term risk, CASI is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check EWTX's competition here
CASI vs ALMS Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, ALMS has a market cap of 3.1B. Regarding current trading prices, CASI is priced at $0.80, while ALMS trades at $29.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas ALMS's P/E ratio is -13.94. In terms of profitability, CASI's ROE is +3.58%, compared to ALMS's ROE of -0.76%. Regarding short-term risk, CASI is more volatile compared to ALMS. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check ALMS's competition here
CASI vs VCYT Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, VCYT has a market cap of 3.1B. Regarding current trading prices, CASI is priced at $0.80, while VCYT trades at $38.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas VCYT's P/E ratio is 101.88. In terms of profitability, CASI's ROE is +3.58%, compared to VCYT's ROE of +0.05%. Regarding short-term risk, CASI is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check VCYT's competition here
CASI vs CPRX Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, CPRX has a market cap of 3.1B. Regarding current trading prices, CASI is priced at $0.80, while CPRX trades at $24.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas CPRX's P/E ratio is 14.55. In terms of profitability, CASI's ROE is +3.58%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CASI is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check CPRX's competition here
CASI vs NAMSW Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, NAMSW has a market cap of 3B. Regarding current trading prices, CASI is priced at $0.80, while NAMSW trades at $25.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas NAMSW's P/E ratio is N/A. In terms of profitability, CASI's ROE is +3.58%, compared to NAMSW's ROE of -0.27%. Regarding short-term risk, CASI is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check NAMSW's competition here
CASI vs VERA Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, VERA has a market cap of 3B. Regarding current trading prices, CASI is priced at $0.80, while VERA trades at $42.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas VERA's P/E ratio is -10.61. In terms of profitability, CASI's ROE is +3.58%, compared to VERA's ROE of -0.50%. Regarding short-term risk, CASI is more volatile compared to VERA. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check VERA's competition here
CASI vs BEAM Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, BEAM has a market cap of 2.9B. Regarding current trading prices, CASI is priced at $0.80, while BEAM trades at $28.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas BEAM's P/E ratio is -6.56. In terms of profitability, CASI's ROE is +3.58%, compared to BEAM's ROE of -0.07%. Regarding short-term risk, CASI is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check BEAM's competition here
CASI vs MORF Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, CASI is priced at $0.80, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas MORF's P/E ratio is -14.88. In terms of profitability, CASI's ROE is +3.58%, compared to MORF's ROE of -0.29%. Regarding short-term risk, CASI is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check MORF's competition here
CASI vs MOR Comparison February 2026
CASI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CASI stands at 3.2M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, CASI is priced at $0.80, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CASI currently has a P/E ratio of -0.07, whereas MOR's P/E ratio is -12.64. In terms of profitability, CASI's ROE is +3.58%, compared to MOR's ROE of -1.84%. Regarding short-term risk, CASI is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for CASI.Check MOR's competition here